Article
Efficacy of low-dose bepridil for prevention of ventricular fibrillation in patients with Brugada syndrome with and without SCN5A mutation.
Journal of cardiovascular pharmacology - 1 Oct 2010
Murakami Masato, Nakamura Kazufumi, Kusano Kengo F, Morita Hiroshi, Nakagawa Koji, Tanaka Masamichi, Tada Takeshi, Toh Norihisa, Nishii Nobuhiro, Nagase Satoshi, Hata Yoshiki, Kohno Kunihisa, Miura Daiji, Ohe Tohru, Ito Hiroshi
Abstract excerpt
It has been reported that bepridil prevents ventricular fibrillation (VF) in patients with Brugada syndrome, but the comparative efficacy with and without mutation in the SCN5A gene has not been elucidated. The purpose of this study was to assess the efficacy of low-dose bepridil (100 mg/day) for VF prevention in patients with Brugada syndrome with and without SCN5A mutation. Among 130 patients with Brugada-type...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.